SecBot SecBot
8-K ·Filed Jul 27, 2026

BSX

BOSTON SCIENTIFIC CORP
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0000885725-26-000049
8-K material event: Items 2.05
Actionable Insight • Neutral

This is a routine cost-efficiency restructuring for a large-cap medtech company. The charges are manageable relative to market cap, and the savings are multi-year. Monitor upcoming quarterly filings for actual charge recognition and any guidance updates, but no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$46.06
T+0 close · Jul 27, 2026 · via day close
Latest settled
−3.37%
T+60 · $44.51
Vs SPY
−7.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 28 $46.06entry
  2. T+1 · 4mo ago −0.04%α +1.50% · $46.04
  3. T+5 · 4mo ago +5.15%α +2.88% · $48.43
  4. T+20 · 3mo ago +8.25%α +4.87% · $49.86
  5. T+60 · 27d ago −3.37%α −7.72% · $44.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Boston Scientific announced a new global restructuring program (2026 Restructuring Plan) approved by its Board on July 21, 2026, aimed at driving cost efficiencies and supporting strategic growth. The plan involves supply chain optimization, functional transformation, and headcount reductions, with estimated total pre-tax charges of $700M-$800M and expected annual pre-tax expense savings of ~$500M, though a substantial portion of savings will be reinvested. For a $65.8B market cap company, the charges are modest (~1.1% of market cap) and the plan is a proactive cost-efficiency move rather than a distress signal, but the lack of specific headcount numbers and multi-year timeline (through 2029) limits near-term impact.

Key Facts

  • Board approved 2026 Restructuring Plan on July 21, 2026.
  • Total estimated pre-tax charges: $700M to $800M.
  • Cash outlays expected: $600M to $700M of total charges.
  • Expected gross annual pre-tax expense reduction: ~$500M.
  • Substantial portion of savings to be reinvested in strategic growth initiatives.
  • Activities include supply chain optimization, production line transfers, functional transformation.
  • Headcount reductions expected but no specific number provided.
  • Plan initiated in 2026, substantially complete by end of 2029.
  • Charge breakdown: Transfer costs $300M-$350M, Termination benefits $275M-$300M, Other $125M-$150M.

Financial Impact

Total pre-tax charges of $700M-$800M (~1.1% of $65.8B market cap), with $600M-$700M in cash outlays. Annual pre-tax expense savings of ~$500M, partially reinvested.

operating expensescash flowpre-tax income

Risk Factors

  • Execution risk on production line transfers and headcount reductions.
  • Potential for higher-than-estimated charges or lower-than-expected savings.
  • Reinvestment of savings may not yield expected growth returns.

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
79% bullish (39 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000885725-26-000049
Document: 0000885725-26-000049-index-headers.html0000885725-26-000049
Document: 0000885725-26-000049-index.html0000885725-26-000049
Document: 0000885725-26-000049.txt0000885725-26-000049

Track record

22 reports on BSX

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +9.24% at T+20 after the Aug 26, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Oct 28, 202619d ago 8-K Bearish 6/10 No price data
  2. Oct 28, 202619d ago Press Release Bearish 5/10 Entry $42.43 Now $43.69 −2.97% settles Nov 25
  3. Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $45.69 Now $43.69 +4.38% settles Nov 20
  4. Oct 7, 20265w ago 8-K Mixed 6/10 Entry $41.58 to $45.82 Now $43.69 +5.07% ▲ +10.20% +11.54% vs SPY
  5. Sep 23, 20267w ago 8-K Bearish 5/10 Entry $44.62 to $44.51 Now $43.69 +2.08% ▲ +0.25% +0.93% vs SPY
  6. Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $48.08 to $43.65 Now $43.69 −9.13% ▼ −9.21% −9.57% vs SPY
  7. Aug 26, 202611w ago 8-K Bearish 6/10 Entry $48.17 to $43.72 Now $43.69 +9.30% ▲ +9.24% +10.44% vs SPY
  8. Aug 22, 202612w ago Institutional Cluster Mixed 6/10 Entry $49.01 to $44.92 Now $43.69 −10.85% ▼ −8.35% −9.66% vs SPY
  9. Aug 7, 202614w ago Insider Cluster Mixed 6/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
  10. Aug 7, 202614w ago Insider Cluster Mixed 5/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026